These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12195266)

  • 21. Pharmacology of therapeutic botulinum toxin preparations.
    Dressler D; Benecke R
    Disabil Rehabil; 2007 Dec; 29(23):1761-8. PubMed ID: 18033601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study.
    Eleopra R; Montecucco C; Devigili G; Lettieri C; Rinaldo S; Verriello L; Pirazzini M; Caccin P; Rossetto O
    Clin Neurophysiol; 2013 May; 124(5):999-1004. PubMed ID: 23245668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clostridium botulinum and botulinum neurotoxin].
    Hirai Y
    Brain Nerve; 2011 Jul; 63(7):755-61. PubMed ID: 21747146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mechanism of action and therapeutic uses of botulinum and tetanus neurotoxins].
    Popoff MR; Marvaud JC; Raffestin S
    Ann Pharm Fr; 2001 May; 59(3):176-90. PubMed ID: 11427819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion.
    Lim EC; Seet RC
    Acta Neurol Scand; 2008 Feb; 117(2):73-84. PubMed ID: 17850405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology and immunology of botulinum toxin serotypes.
    Aoki KR
    J Neurol; 2001 Apr; 248 Suppl 1():3-10. PubMed ID: 11357237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myofiber length and three-dimensional localization of NMJs in normal and botulinum toxin treated adult extraocular muscles.
    Harrison AR; Anderson BC; Thompson LV; McLoon LK
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3594-601. PubMed ID: 17652728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different types of botulinum toxin in humans.
    Eleopra R; Tugnoli V; Quatrale R; Rossetto O; Montecucco C
    Mov Disord; 2004 Mar; 19 Suppl 8():S53-9. PubMed ID: 15027055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides.
    Matarasso SL
    Dermatol Surg; 2003 Jan; 29(1):7-13; discussion 13. PubMed ID: 12534505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A.
    Sloop RR; Escutin RO; Matus JA; Cole BA; Peterson GW
    Neurology; 1996 May; 46(5):1382-6. PubMed ID: 8628486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.
    Turton K; Chaddock JA; Acharya KR
    Trends Biochem Sci; 2002 Nov; 27(11):552-8. PubMed ID: 12417130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species.
    Chen F; Kuziemko GM; Stevens RC
    Infect Immun; 1998 Jun; 66(6):2420-5. PubMed ID: 9596697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain.
    Zhang L; Lin WJ; Li S; Aoki KR
    Gene; 2003 Oct; 315():21-32. PubMed ID: 14557061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The current use of botulinum toxin.
    Mahant N; Clouston PD; Lorentz IT
    J Clin Neurosci; 2000 Sep; 7(5):389-94. PubMed ID: 10942658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxins: mechanisms of action, antinociception and clinical applications.
    Wheeler A; Smith HS
    Toxicology; 2013 Apr; 306():124-46. PubMed ID: 23435179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum toxin type B in the treatment of anal fissures: first preliminary results.
    Jost WH
    Dis Colon Rectum; 2001 Nov; 44(11):1721-2. PubMed ID: 11719933
    [No Abstract]   [Full Text] [Related]  

  • 38. Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells.
    Purkiss JR; Friis LM; Doward S; Quinn CP
    Neurotoxicology; 2001 Aug; 22(4):447-53. PubMed ID: 11577803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use.
    Hambleton P
    J Neurol; 1992 Jan; 239(1):16-20. PubMed ID: 1311751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
    Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.